{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:12Z","timestamp":1792161072195,"version":"4.4.0"},"reference-count":66,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"CONTEXT:<\/jats:title>Legalization of medical marijuana in many states has led to a widening gap between the accessibility and the evidence for cannabinoids as a medical treatment.<\/jats:p><\/jats:sec>OBJECTIVE:<\/jats:title>To systematically review published reports to identify the evidence base of cannabinoids as a medical treatment in children and adolescents.<\/jats:p><\/jats:sec>DATA SOURCES:<\/jats:title>Based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a search of PubMed, Medline, and the Cumulative Index to Nursing and Allied Health Literature databases was conducted in May 2017.<\/jats:p><\/jats:sec>STUDY SELECTION:<\/jats:title>Searching identified 2743 citations, and 103 full texts were reviewed.<\/jats:p><\/jats:sec>DATA EXTRACTION:<\/jats:title>Searching identified 21 articles that met inclusion criteria, including 22 studies with a total sample of 795 participants. Five randomized controlled trials, 5 retrospective chart reviews, 5 case reports, 4 open-label trials, 2 parent surveys, and 1 case series were identified.<\/jats:p><\/jats:sec>RESULTS:<\/jats:title>Evidence for benefit was strongest for chemotherapy-induced nausea and vomiting, with increasing evidence of benefit for epilepsy. At this time, there is insufficient evidence to support use for spasticity, neuropathic pain, posttraumatic stress disorder, and Tourette syndrome.<\/jats:p><\/jats:sec>LIMITATIONS:<\/jats:title>The methodological quality of studies varied, with the majority of studies lacking control groups, limited by small sample size, and not designed to test for the statistical significance of outcome measures. Studies were heterogeneous in the cannabinoid composition and dosage and lacked long-term follow-up to identify potential adverse effects.<\/jats:p><\/jats:sec>CONCLUSIONS:<\/jats:title>Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents, especially given increasing accessibility from state legalization and potential psychiatric and neurocognitive adverse effects identified from studies of recreational cannabis use.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2017-1818","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:36:41Z","timestamp":1508773001000},"source":"Crossref","is-referenced-by-count":121,"title":["Medical Cannabinoids in Children and Adolescents: A Systematic Review"],"prefix":"10.1542","volume":"140","author":[{"given":"Shane Shucheng","family":"Wong","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Wilens","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"issue":"4","key":"2021121106555185000_B1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids.","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021121106555185000_B2","unstructured":"Solvay Pharmaceuticals, Inc. Marinol. 2004. Available at: https:\/\/www.fda.gov\/ohrms\/dockets\/dockets\/05n0479\/05N-0479-emc0004-04.pdf. Accessed January 28, 2017"},{"key":"2021121106555185000_B3","unstructured":"Valeant Pharmaceuticals International. Cesamet. 2006. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018677s011lbl.pdf. Accessed January 28, 2017"},{"key":"2021121106555185000_B4","unstructured":"National Conference of State Legislatures . State medical marijuana laws. 2016. Available at: www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx. Accessed January 28, 2017"},{"issue":"3","key":"2021121106555185000_B5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1542\/peds.2014-4147","article-title":"The impact of marijuana policies on youth: clinical, research, and legal update.","volume":"135","author":"Ammerman","year":"2015","journal-title":"Pediatrics"},{"issue":"7","key":"2021121106555185000_B6","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"6","key":"2021121106555185000_B7","first-page":"462","article-title":"Characterization of dronabinol usage in a pediatric oncology population.","volume":"20","author":"Elder","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"23\u201324","key":"2021121106555185000_B8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/0024-3205(95)00194-B","article-title":"An efficient new cannabinoid antiemetic in pediatric oncology.","volume":"56","author":"Abrahamov","year":"1995","journal-title":"Life Sci"},{"issue":"6","key":"2021121106555185000_B9","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"issue":"5","key":"2021121106555185000_B10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/adc.61.5.502","article-title":"Nabilone: an alternative antiemetic for cancer chemotherapy.","volume":"61","author":"Dalzell","year":"1986","journal-title":"Arch Dis Child"},{"issue":"12","key":"2021121106555185000_B11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","article-title":"Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.","volume":"2","author":"Ekert","year":"1979","journal-title":"Med J Aust"},{"issue":"21","key":"2021121106555185000_B12","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121106555185000_B13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases.","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J Child Neurol"},{"key":"2021121106555185000_B14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.02.009","article-title":"Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome.","volume":"71","author":"Kaplan","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"1","key":"2021121106555185000_B15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/epi.13617","article-title":"Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients.","volume":"58","author":"Treat","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"2021121106555185000_B16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"2021121106555185000_B17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience.","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"2021121106555185000_B18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome.","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav"},{"key":"2021121106555185000_B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"5","key":"2021121106555185000_B20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pediatrneurol.2015.02.008","article-title":"Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.","volume":"52","author":"Saade","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"3","key":"2021121106555185000_B21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"1\u20132","key":"2021121106555185000_B22","first-page":"40","article-title":"On the application of cannabis in paediatrics and epileptology.","volume":"25","author":"Lorenz","year":"2004","journal-title":"Neuroendocrinol Lett"},{"issue":"4","key":"2021121106555185000_B23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1155\/2003\/675976","article-title":"Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents.","volume":"8","author":"Rudich","year":"2003","journal-title":"Pain Res Manag"},{"issue":"4","key":"2021121106555185000_B24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7812\/TPP\/16-005","article-title":"Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report.","volume":"20","author":"Shannon","year":"2016","journal-title":"Perm J"},{"issue":"6","key":"2021121106555185000_B25","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ejpn.2016.07.021","article-title":"Effective treatment of spasticity using dronabinol in pediatric palliative care.","volume":"20","author":"Kuhlen","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"issue":"5\u20136","key":"2021121106555185000_B26","first-page":"387","article-title":"A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky.","volume":"23","author":"Lorenz","year":"2002","journal-title":"Neuroendocrinol Lett"},{"issue":"2","key":"2021121106555185000_B27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","article-title":"Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.","volume":"30","author":"Hasan","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"2021121106555185000_B28","first-page":"CD009464","article-title":"Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021121106555185000_B29","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"issue":"24","key":"2021121106555185000_B30","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis.","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"2021121106555185000_B31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data.","volume":"16","author":"Andreae","year":"2015","journal-title":"J Pain"},{"key":"2021121106555185000_B32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study.","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"2021121106555185000_B33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.4088\/JCP.14m09475","article-title":"Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.","volume":"76","author":"Wilkinson","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2021121106555185000_B34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.","volume":"64","author":"M\u00fcller-Vahl","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2021121106555185000_B35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette\u2019s syndrome with \u0394 9-tetrahydrocannabinol (THC): a randomized crossover trial.","volume":"35","author":"M\u00fcller-Vahl","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"13","key":"2021121106555185000_B36","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1503\/cmaj.071178","article-title":"Adverse effects of medical cannabinoids: a systematic review.","volume":"178","author":"Wang","year":"2008","journal-title":"CMAJ"},{"issue":"4","key":"2021121106555185000_B37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00431-017-2872-5","article-title":"A 10-year review of cannabis exposure in children under 3-years of age: do we need a more global approach?","volume":"176","author":"Claudet","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2021121106555185000_B38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain.","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"issue":"23","key":"2021121106555185000_B39","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1073\/pnas.0703472104","article-title":"[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.","volume":"104","author":"Burns","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121106555185000_B40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fpsyt.2013.00053","article-title":"Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function.","volume":"4","author":"Lisdahl","year":"2013","journal-title":"Front Psychiatry"},{"issue":"1","key":"2021121106555185000_B41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1196\/annals.1308.053","article-title":"Impact of cannabis use on brain function in adolescents.","volume":"1021","author":"Jacobsen","year":"2004","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2021121106555185000_B42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2006.02.014","article-title":"Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users.","volume":"61","author":"Jacobsen","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2021121106555185000_B43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1369-1600.2009.00166.x","article-title":"Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects.","volume":"14","author":"Medina","year":"2009","journal-title":"Addict Biol"},{"issue":"40","key":"2021121106555185000_B44","doi-asserted-by":"crossref","first-page":"E2657","DOI":"10.1073\/pnas.1206820109","article-title":"Persistent cannabis users show neuropsychological decline from childhood to midlife.","volume":"109","author":"Meier","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2021121106555185000_B45","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1073\/pnas.1516648113","article-title":"Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies.","volume":"113","author":"Jackson","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2021121106555185000_B46","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1073\/pnas.1215678110","article-title":"Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status.","volume":"110","author":"Rogeberg","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2021121106555185000_B47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00213-011-2203-x","article-title":"Verbal learning and memory in adolescent cannabis users, alcohol users and non-users.","volume":"216","author":"Solowij","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"2021121106555185000_B48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.15288\/jsad.2015.76.738","article-title":"Effects of emerging alcohol and marijuana use behaviors on adolescents\u2019 neuropsychological functioning over four years.","volume":"76","author":"Nguyen-Louie","year":"2015","journal-title":"J Stud Alcohol Drugs"},{"issue":"7","key":"2021121106555185000_B49","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1017\/S1355617702870011","article-title":"Substance use and withdrawal: neuropsychological functioning over 8 years in youth.","volume":"8","author":"Tapert","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"2021121106555185000_B50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002130050892","article-title":"Specific attentional dysfunction in adults following early start of cannabis use.","volume":"142","author":"Ehrenreich","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"2021121106555185000_B51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1192\/bjp.bp.110.077479","article-title":"Cannabis use before age 15 and subsequent executive functioning.","volume":"198","author":"Fontes","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"3","key":"2021121106555185000_B52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0376-8716(02)00334-4","article-title":"Early-onset cannabis use and cognitive deficits: what is the nature of the association?","volume":"69","author":"Pope","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2021121106555185000_B53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum Psychopharmacol"},{"issue":"1\u20132","key":"2021121106555185000_B54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2010.11.004","article-title":"Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).","volume":"115","author":"Lopez-Quintero","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"2021121106555185000_B55","first-page":"58","volume-title":"Cannabis Dependence: Its Nature, Consequences and Treatment","author":"Anthony","year":"2006"},{"issue":"4","key":"2021121106555185000_B56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(01)00367-0","article-title":"From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol.","volume":"26","author":"Wagner","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"2021121106555185000_B57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.289.4.427","article-title":"Escalation of drug use in early-onset cannabis users vs co-twin controls.","volume":"289","author":"Lynskey","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"2021121106555185000_B58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/chi.0b013e31802dc54d","article-title":"Cannabis and anxiety and depression in young adults: a large prospective study.","volume":"46","author":"Hayatbakhsh","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121106555185000_B59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2014.10.006","article-title":"The association between cannabis use and mood disorders: a longitudinal study.","volume":"172","author":"Feingold","year":"2015","journal-title":"J Affect Disord"},{"issue":"10","key":"2021121106555185000_B60","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/archpsyc.61.10.1026","article-title":"Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use.","volume":"61","author":"Lynskey","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2021121106555185000_B61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.2008.01259.x","article-title":"Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study.","volume":"118","author":"Pedersen","year":"2008","journal-title":"Acta Psychiatr Scand"},{"issue":"7374","key":"2021121106555185000_B62","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.","volume":"325","author":"Arseneault","year":"2002","journal-title":"BMJ"},{"issue":"8","key":"2021121106555185000_B63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1176\/appi.ajp.2016.15070878","article-title":"Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms.","volume":"173","author":"Bechtold","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"11","key":"2021121106555185000_B64","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1046\/j.1360-0443.2000.951116213.x","article-title":"The effects of adolescent cannabis use on educational attainment: a review.","volume":"95","author":"Lynskey","year":"2000","journal-title":"Addiction"},{"issue":"2","key":"2021121106555185000_B65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1192\/bjp.188.2.148","article-title":"Cannabis use and mental health in secondary school children. Findings from a Dutch survey.","volume":"188","author":"Monshouwer","year":"2006","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2021121106555185000_B66","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1360-0443.2008.02221.x","article-title":"Cannabis use and later life outcomes.","volume":"103","author":"Fergusson","year":"2008","journal-title":"Addiction"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-1818\/909901\/peds_20171818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-1818\/909901\/peds_20171818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T23:08:24Z","timestamp":1719529704000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/140\/5\/e20171818\/37884\/Medical-Cannabinoids-in-Children-and-Adolescents-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-1818","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]},"article-number":"e20171818"}}